{"nctId":"NCT00361218","briefTitle":"Biological Markers of Response to Treatment in Major Depressive Disorder","startDateStruct":{"date":"2005-10"},"conditions":["Major Depressive Disorder"],"count":72,"armGroups":[{"label":"open-label selective serotonin reuptake inhibitor (SSRI)","type":"OTHER","interventionNames":["Drug: open-label selective serotonin reuptake inhibitor (SSRI)"]}],"interventions":[{"name":"open-label selective serotonin reuptake inhibitor (SSRI)","otherNames":["escitalopram or citalopram"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 18-65\n* Meet criteria for current Major Depressive Disorder\n* Antidepressant medication-free for at least 2 weeks prior to the start of the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Anyone who is suicidal\n* Anyone with an unstable medical condition (cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological), substance abuse problem within the past 6 months, psychoses (past or current), hypothyroidism, or hypomania\n* Anyone currently taking an SSRI\n* Past intolerance to Lexapro or Celexa","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Brain-derived Neurotrophic Factor (BDNF) Levels","description":"\"Pre-SSRI BDNF Level\" refers to the data collection point before SSRI intake and \"Post-SSRI BDNF Level\" refers to the data collection point 8 weeks after SSRI intake.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6077.270","spread":"4371.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4393.24","spread":"3263.70"}]}]}]},{"type":"PRIMARY","title":"Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response","description":"Pre-treatment quantitative electroencephalogram (QEEG) refers to the data collection point before selective serotonin reuptake inhibitor (SSRI) treatment and Post-treatment QEEG refers to the data collection point 8 weeks after SSRI treatment initiation.\n\nResponse refers to a greater than 50% decrease in Hamiton Depression Rating Scale from baseline, which ranges from 0 (no depression) to a maximum of 54 (severe depression).","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["weight gain","lack of appetite","increase in tremors","nausea","hypomania"]}}}